Cost-effectiveness of Direct Oral Anticoagulant vs. Warfarin Among Atrial Fibrillation Patients With Intermediate Stroke Risk

被引:10
作者
Choi, Ju Hee [1 ]
Kim, Woojin [2 ]
Kim, Yun Tae [1 ]
Cho, Jaelim [2 ]
Shin, Seung Yong [3 ]
Kim, Changsoo [2 ,4 ]
Kim, Jin-Bae [5 ]
机构
[1] Yonsei Univ, Grad Sch, Dept Publ Hlth, Seoul, South Korea
[2] Yonsei Univ, Dept Prevent Med, Coll Med, Seoul, South Korea
[3] Chung Ang Univ Hosp, Div Cardiol, Seoul, South Korea
[4] Yonsei Univ, Inst Human Complex & Syst Sci, Incheon, South Korea
[5] Kyung Hee Univ, Kyung Hee Univ Hosp, Dept Internal Med, Div Cardiol, Seoul, South Korea
来源
FRONTIERS IN CARDIOVASCULAR MEDICINE | 2022年 / 9卷
关键词
atrial fibrillation; cost-effectiveness; anticoagulants; warfarin; intermediate stroke risk; CLINICAL-FEATURES; PREVENTION; APIXABAN; ASPIRIN; EPIDEMIOLOGY; RIVAROXABAN; DABIGATRAN;
D O I
10.3389/fcvm.2022.849474
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundSeveral studies have shown the cost-effectiveness of direct oral anticoagulants (DOACs), compared with warfarin, to prevent atrial fibrillation (AF) related complications. However, few have reported cost-effectiveness of DOACs in AF patients with intermediate stroke risk. Thus, we investigated the cost-effectiveness of DOACs vs. warfarin in non-valvular AF patients with intermediate stroke risk using national representative data. MethodsWe identified 7,954 newly diagnosed non-valvular AF patients (>= 18 years) with intermediate stroke risk (CHA(2)DS(2)-VASc score: 1 for men and 2 for women) using the national healthcare utilization data from August 1, 2016, to July 31, 2019. Annual incidence rate of AF-related composite outcomes (heat failure, myocardial infarction, ischemic stroke, intracerebral hemorrhage, and gastrointestinal bleeding) was estimated. Cost-effectiveness was estimated using a Markov chain model with the transition probability of 1 year. The willingness-to-pay (WTP) was set at $32,000 per quality-adjusted life-year (QALY) gained. ResultsThe total cost of warfarin, rivaroxaban, apixaban, dabigatran and edoxaban was $2,874, $5,761, $5,151, $5,761 and $5,851, respectively. The QALYs gained were 10.83, 10.95, 11.10, 10.49 and 10.99 years, respectively. The incremental cost-effectiveness ratio of rivaroxaban, apixaban, dabigatran and edoxaban was $29,743.99, $8,426.71, -$8,483.04 and $18,483.55, respectively. The WTP was set at $32,000. DOACs (except dabigatran) were more cost-effective compared with warfarin because they did not exceed the WTP in the base-case analysis. ConclusionOur findings showed that DOACs were more cost-effective than warfarin in non-valvular AF patients with intermediate stroke risk.
引用
收藏
页数:7
相关论文
共 37 条
[1]   The Clinical Profile and Pathophysiology of Atrial Fibrillation Relationships Among Clinical Features, Epidemiology, and Mechanisms [J].
Andrade, Jason ;
Khairy, Paul ;
Dobrev, Dobromir ;
Nattel, Stanley .
CIRCULATION RESEARCH, 2014, 114 (09) :1453-1468
[2]   Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective [J].
Athanasakis, Kostas ;
Boubouchairopoulou, Nadia ;
Karampli, Eleftheria ;
Tarantilis, Filippos ;
Savvari, Paraskevi ;
Bilitou, Aikaterini ;
Kyriopoulos, John .
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2017, 17 (02) :123-133
[3]   Cost-Effectiveness of Apixaban vs. Other New Oral Anticoagulants for the Prevention of Stroke: An Analysis on Patients with Non-Valvular Atrial Fibrillation in the Greek Healthcare Setting [J].
Athanasakis, Kostas ;
Karampli, Eleftheria ;
Tsounis, Dimitrios ;
Bilitou, Aikaterini ;
Kyriopoulos, John .
CLINICAL DRUG INVESTIGATION, 2015, 35 (11) :693-705
[4]   Cost-Effectiveness Analysis of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Thai Patients With Non-Valvular Atrial Fibrillation [J].
Dilokthornsakul, Piyameth ;
Nathisuwan, Surakit ;
Krittayaphong, Rungroj ;
Chutinet, Aurauma ;
Permsuwan, Unchalee .
HEART LUNG AND CIRCULATION, 2020, 29 (03) :390-400
[5]   Atrial fibrillation in the elderly [J].
Fang, Margaret C. ;
Chen, Jane ;
Rich, Michael W. .
AMERICAN JOURNAL OF MEDICINE, 2007, 120 (06) :481-487
[6]   Systematic review of cost-effectiveness analyses of novel oral anticoagulants for stroke prevention in atrial fibrillation [J].
Ferreira, Joao ;
Mirco, Ana .
REVISTA PORTUGUESA DE CARDIOLOGIA, 2015, 34 (03) :179-191
[7]   The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life [J].
Gage, BF ;
Cardinalli, AB ;
Owens, DK .
ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (16) :1829-1836
[8]  
Health Insurance Review and Assessment Service (HIRA), 2021, GUID EC EV PHARM KOR
[9]   Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia [J].
Hersi, Ahmad S. ;
Osenenko, Katherine M. ;
Kherraf, Sid Ahmed ;
Aziz, Ayman Abdel ;
Sambrook, Robert Joseph .
ANNALS OF SAUDI MEDICINE, 2019, 39 (04) :265-278
[10]  
Hindricks G, 2021, EUR HEART J, V42, P507, DOI 10.1093/eurheartj/ehaa798